title: Apolipoprotein A-I mimetics.
abstract: OBJECTIVE
  To summarize recent publications in the field of apolipoprotein mimetics.
  
  
  RESULTS
  Apolipoprotein mimetic peptides continue to show efficacy in a number of animal models of disease and demonstrate properties that make them attractive as potential therapeutic agents. A number of new apolipoprotein mimetics have been described recently. A major site of action of apolipoprotein mimetic peptides was found to be in the small intestine in which they decrease the levels of proinflammatory bioactive lipids. A major problem related to the use of apolipoprotein mimetic peptides is their cost, particularly those that need to be generated by solid phase synthesis with chemical addition of end-blocking groups. Novel approaches to apolipoprotein mimetic therapy have emerged recently that show promise in overcoming these barriers.
  
  
  CONCLUSIONS
  Despite the recent failure of therapies designed to raise HDL-cholesterol in humans, an approach to therapy using mimetics of HDL and its components continues to show promise.
authors: aDepartment of Medicine bDepartment of Obstetrics and Gynecology cDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California dDepartment of Medicine, University of Alabama at Birmingham, Alabama USA.
authors: Srinivasa T
authors: ST
authors: Reddy
authors: Mohamad
authors: M
authors: Navab
authors: Gattadahalli M
authors: GM
authors: Anantharamaiah
authors: Alan M
authors: AM
authors: Fogelman
mesh_terms: D000818:Animals; D016632:Apolipoprotein A-I / Q000737:chemistry*; D032701:Biomimetics / Q000379:methods*; D004194:Disease; D006801:Humans; D057786:Peptidomimetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D016632:Apolipoprotein A-I; D057786:Peptidomimetics